Company News Summary | 22 Apr 2021
Click the print icon in your browser to print this report. Currency is in AUD unless otherwise specified
Australian Pharmaceutical Industries Provides HY 2021 Results Presentation
09:19:00 | Associate analysts
Original annuncemenet:API HY21 Results Presentation
Australian Pharmaceutical Industries provided HY 2021 results presentation. It reported revenue is resilient in the face of COVID down 2.6% on the pcp. The Underlying EBITDA is down 11.8% and Underlying EBIT is down 26.5% on the pcp reflecting lockdown restrictions and low foot traffic in CBD stores. It declared dividend of 1.5c for H1 2021, representing a payout of 47% of NPAT.
|This report appeared on www.morningstar.com.au||2021 Morningstar Australasia Pty Limited|
© Copyright 2021 Morningstar Australasia Pty Ltd ABN: 95 090 665 544 ("Morningstar"), AFSL no 240892. (a subsidiary of Morningstar, Inc.). This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written content of Morningstar. Some of the material provided is published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO").